ClinicalTrials.gg
Active, not recruitingNCT07076199ONWARDS 11Updated Sep 25, 2026

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

A Phase 3 interventional study of Insulin icodec and Insulin glargine in Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Active, not recruiting at 182 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
877
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S — 2 open to participants now, 5 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · Novo Nordisk A/S.

Planned enrollment
5th of 149
877 · median 62
Started
2025
with 6 others
Phase 3
54 of 226
none open now
Registered
223rd of 226
by date

Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, this one is the 5th largest by planned enrollment of the 149 interventional ones that give a count, is one of 7 that started in 2025, is one of 54 in phase 3, and was the 223rd registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. The study will last for about 8.5 months.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with type 1 diabetes mellitus greater than or equal to (≥) 1 year before screening.
  • Treated with multiple daily insulin injections (daily basal insulin analogue and bolus insulin analogue regimen) ≥ 6 months before screening.
  • from 7.0-10.0 percentage (%) (53.0-85.8 millimoles per mole (mmol/mol)), both inclusive, at screening confirmed by central laboratory analysis.
  • Ability and willingness to adhere to the protocol including performance of self-measured plasma glucose (SMPG) profiles, based on the investigator's judgement.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to study intervention(s) or related products.
  • Previous participation in this study. Participation is defined as signed .
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using adequate method.
  • Exposure to an medicinal product within 90 days or 5 half-lives of the investigational medicinal product (if known), whichever is longer, before screening.
  • Any condition, except for conditions associated with type 1 diabetes mellitus, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
  • Anticipated initiation or anticipated change in concomitant medications (for more than 15 consecutive days) known to affect weight or glucose metabolism (e.g., treatment with thyroid hormones, or systemic ).
  • Known hypoglycaemic unawareness as indicated by the Investigator according to Clarke's questionnaire question.
  • Recurrent severe hypoglycaemic episodes within the last year as judged by the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
877 participants (estimated)

Study arms

  • Experimental
    Insulin icodec + insulin aspart

    Participants will receive subcutaneously once weekly insulin icodec in combination with 2-4 times daily insulin aspart .

    Drug: Insulin icodec · Drug: Insulin aspart

  • Active comparator
    Insulin glargine+ insulin aspart

    Participants will receive subcutaneously once daily insulin glargine in combination with 2-4 times daily insulin aspart.

    Drug: Insulin glargine · Drug: Insulin aspart

Interventions

  • Insulin icodec will be administered as subcutaneous injection

  • Insulin glargine will be administered as subcutaneous injection.

  • Insulin aspart will be administered as a subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Change in glycosylated haemoglobin (HbA1c)

    Measured in percentage (%)-points.

    Time frame: From baseline (week 0) to week 26

Secondary outcomes

  1. Change in time in range 3.9-10.0 millimoles per liter (mmol/L) (70-180 milligrams per deciliter (mg/dL))

    Measured in %-points.

    Time frame: From baseline (week-2-0) to week 22-26

  2. Time spent less than (<)3.0 mmol/L (54 mg/dL)

    Measured in % of time.

    Time frame: From week 22 to week 26

  3. Change in time spent greater than (>)10.0 mmol/L (180 mg/dL)

    Measured in %-points.

    Time frame: From baseline (week-2-0) to week 22-26

  4. Number of severe hypoglycaemic episodes (level 3)

    Measured as number of episodes.

    Time frame: From baseline (week 0) to week 31

  5. Number of clinically significant hypoglycaemicepisodes (level 2) (<3.0mmol/L [54 mg/dL],confirmed by blood glucose (BG) meter)

    Measured as number of episodes.

    Time frame: From baseline (week 0) to week 31

  6. Number of clinically significant hypoglycaemic episodes (level 2) (< 3.0 mmol/L [54 mg/dL], severe hypoglycaemic confirmed by BG meter) or episodes (level 3)

    Measured as number of episodes.

    Time frame: From baseline (week 0) to week 31

  7. Number of continuous glucose continuous glucose (CGM)-based clinically significant hypoglycaemic episodes (level 2) (< 3.0 mmol/L [54 mg/dL])

    Measured as number of episodes.

    Time frame: From baseline (week 0) to week 31

  8. Mean total weekly insulin dose

    Measured in insulin units.

    Time frame: From week 24 to week 26

  9. Change in body weight

    Measured in Kilogram (kg).

    Time frame: From baseline (week 0) to week 26

07

Study locations

182 sites

Showing the first 100 of 182 sites across 8 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jan 2027, 17 months after the start.

Of 78 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's planned 17 months is close to that.

Counting every sponsor, half of 106 studies reached it within 18 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2025
First posted
Jul 22, 2025
StartActual
Aug 11, 2025
Primary completionEst.
Jan 25, 2027
CompletionEst.
Mar 1, 2027
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07076199
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 22, 2025
Start date
Aug 11, 2025
Primary completion
Jan 25, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin icodec

Start the discussion